文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.

作者信息

Day Eric S, Cachero Teresa G, Qian Fang, Sun Yaping, Wen Dingyi, Pelletier Marc, Hsu Yen-Ming, Whitty Adrian

机构信息

Department of Drug Discovery, Biogen Idec, Inc., 14 Cambridge Center, Cambridge, Massachusetts 02142, USA.

出版信息

Biochemistry. 2005 Feb 15;44(6):1919-31. doi: 10.1021/bi048227k.


DOI:10.1021/bi048227k
PMID:15697217
Abstract

BAFF (B cell activating factor of the TNF family, also known as BlyS and TALL-1), a TNF family cytokine critical for the development and function of B cells, has been reported to bind to three receptors, BCMA (B cell maturation protein), TACI (transmembrane activator and CAML [calcium-modulator and cyclophilin ligand] interactor), and BAFFR (BAFF receptor), but with widely conflicting values for the affinity and selectivity of binding. BCMA and TACI additionally bind APRIL (a proliferation-inducing ligand), the TNF family ligand most homologous to BAFF. Using soluble, monomeric forms of the receptors, we demonstrate that BAFFR binds BAFF with K(D) approximately 16 nM, while BCMA binds with K(D) approximately 1.6 microM, indicating a approximately 100-fold selectivity for binding to BAFFR over BCMA. APRIL shows the opposite selectivity, binding to BCMA with K(D) approximately 16 nM while showing no detectable affinity for BAFFR (K(D) > 3 microM). The binding of BAFF or APRIL to these receptors is highly sensitive to assay-dependent avidity effects, likely explaining the widely ranging affinity values reported in the literature. Binding of BAFF to BCMA-Fc, a bivalent fusion protein consisting of the extracellular domain of BCMA fused to the hinge and CH1 and CH2 domains of human IgG1, in solution or coated onto an ELISA plate gave apparent binding affinities of approximately 0.63 and approximately 0.15 nM, respectively, compared to values of K(D(app)) <or= 30 and approximately 100 pM for the corresponding BAFFR/IgG1 fusion protein, BAFFR-Fc. The high selectivity of BAFF for BAFFR versus BCMA is thus partly obscured in these multivalent assays. The intrinsically high selectivity inferred from the measurements with monomeric receptor correlates well with in vivo data from knockout mice, providing a possible explanation for the observations that interruption of the BAFFR gene in the A/WySnJ mouse produces a phenotype similar to the BAFF knockout mouse, while the BCMA knockout mouse has no discernible B cell phenotype.

摘要

相似文献

[1]
Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA.

Biochemistry. 2005-2-15

[2]
Identification of proteoglycans as the APRIL-specific binding partners.

J Exp Med. 2005-5-2

[3]
BAFF/BLyS receptor 3 comprises a minimal TNF receptor-like module that encodes a highly focused ligand-binding site.

Biochemistry. 2003-5-27

[4]
BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF.

Science. 2001-9-14

[5]
B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses.

Mol Cell Biol. 2001-6

[6]
Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue development.

J Immunol. 2009-11-1

[7]
BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors.

Int Immunol. 2005-6

[8]
Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion.

Eur J Immunol. 2007-7

[9]
The uncertain glory of APRIL.

Cell Death Differ. 2003-10

[10]
Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes.

J Mol Biol. 2002-2-1

引用本文的文献

[1]
Telitacicept treatment for recurrent IgA nephropathy after kidney transplantation.

Clin Kidney J. 2025-7-16

[2]
Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma.

Cells. 2025-7-15

[3]
The role of B cell-activating factor system in autoimmune diseases: mechanisms, disease implications, and therapeutic advances.

Front Immunol. 2025-6-6

[4]
Advances in adoptive cellular immunotherapy and therapeutic breakthroughs in multiple myeloma.

Exp Hematol Oncol. 2024-10-28

[5]
New Insights and Future Perspectives of APRIL in IgA Nephropathy.

Int J Mol Sci. 2024-9-26

[6]
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma.

Cancers (Basel). 2024-6-26

[7]
Role of telitacicept in the treatment of IgA nephropathy.

Eur J Med Res. 2023-9-22

[8]
Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review.

J Clin Med. 2023-8-25

[9]
Targeting B Cell Maturation Antigen in Patients with Multiple Myeloma: Current Perspectives.

Onco Targets Ther. 2023-6-20

[10]
Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses.

Cell Rep. 2023-7-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索